TruSight Oncology 500 DNA Kit plus PierianDx interpretation report (16 indexes, 48 Samples)
20032624
TruSight Oncology 500 DNA Kit for Use with NextSeq plus PierianDx interpretation report (16 indexes, 48 Samples)
20032625
TruSight Oncology 500 DNA/RNA Bundle plus PierianDx interpretation report (16 indexes, 24 Samples)
20032626
TruSight Oncology 500 DNA/RNA Kit for Use with NextSeq plus PierianDx interpretation report (16 indexes, 24 Samples)
20032627
TruSight Oncology 500 DNA Automation Kit + PierianDx plus PierianDx interpretation report (16 indexes, 64 samples)
20045506
TruSight Oncology 500 DNA Automation Kit plus PierianDx interpretation report, for Use with NextSeq + PierianDx (16 indexes, 64 samples)
20045507
TruSight Oncology 500 DNA/RNA Automation Kit plus PierianDx interpretation report (16 indexes, 32 Samples)
20045509
TruSight Oncology 500 DNA/RNA Automation Kit, For Use with NextSeq (16 indexes, 32 Samples)
20045990
TruSight Oncology 500 DNA/RNA Automation Kit plus PierianDx interpretation report, For Use with NextSeq (16 indexes, 32 Samples)
20045991
TruSight Oncology 500は腫瘍サンプルから施設内での包括的ゲノムプロファイリングが実施可能な次世代シーケンサー(NGS)アッセイです。さまざまな種類の固形腫瘍との関連が示唆されるすべてのDNAとRNAバリアントの同定に役立ちます。
さらに、マイクロサテライト不安定性(MSI)や腫瘍変異負荷(TMB)といった既知の重要な免疫腫瘍学バイオマーカーの精確な測定も可能です。
複数のバイオマーカーを一つのアッセイに統合
合理化されたサンプルから結果を得るまでのワークフロー
高い信頼性の結果を達成
施設内での包括的ゲノムプロファイリングの実現
TruSight Oncology 500製品ポートフォリオに含まれる3つのアッセイはすべて、ガイドラインや臨床試験に含まれる重要なバイオマーカーを同定するように設計されています。
TruSight Oncology 500アッセイを用いて、FFPE腫瘍組織から関連バイオマーカーを評価します。
TruSight Oncology 500アッセイ同様、同じバイオマーカーと同じ種類の組織を用いて、一回192検体まで解析できます。
TruSight Oncology 500 ctDNAアッセイを用いて血漿から血中循環腫瘍DNAを解析します。
フォームにご記入いただくと、TruSight Oncology 500初回購入プログラムに関する情報を受け取ることができます。
TruSight Oncology 500 | TruSight Oncology 500 High-Throughput | TruSight Oncology 500 ctDNA | |
---|---|---|---|
Cancer Type | Pan-Cancer | Pan-Cancer | Pan-Cancer |
Content Specifications | Targeted selection of DNA from 523 genes of interest, and RNA from 55 genes, for a total of 1.94Mb panel size. • Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types • Clinical Trials Coverage: Over 1,000 clinical trials • Immuno-oncology Biomarker Coverage: Biomarkers TMB and MSI included; also inclusive of HLA regions, POLE1 and POLD1* |
Targeted selection of DNA from 523 genes of interest, and RNA from 55 genes, for a total of 1.94Mb panel size. • Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types • Clinical Trials Coverage: Over 1,000 clinical trials • Immuno-oncology Biomarker Coverage: Biomarkers TMB and MSI included; also inclusive of HLA regions, POLE1 and POLD1* |
Targeted selection of 523 genes (full coding sequence) for a total of 1.94Mb panel size. • Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types • Immuno-oncology Biomarker Coverage: TMB and MSI* |
Hands-On Time | ~10.5 hours | Manual: ~10.5 hrs Automated: ~2.5 hrs |
Manual: ~10.5 hrs Automated: N/A |
Input Quantity | 40 ng DNA, 40 ng RNA | 40 ng DNA, 40-80 ng RNA (need at least 2 mm3 FFPE tissue) | 30 ng cfDNA (8-10 ml of plasma) |
Method | Target Enrichment, Target Enrichment, Targeted DNA Sequencing, Targeted RNA Sequencing | Target Enrichment, Target Enrichment, Targeted DNA Sequencing, Targeted RNA Sequencing | Target Enrichment, Target Enrichment, Targeted DNA Sequencing |
Nucleic Acid Type | RNA, DNA | RNA, DNA | DNA |
Specialized Sample Types | FFPE Tissue | FFPE Tissue | Blood, Circulating Tumor DNA |
Species Category | Human | Human | Human |
System Compatibility | NextSeq 500, NextSeq 550, NextSeq 550Dx in Research Mode | NovaSeq 6000 | NovaSeq 6000 |
Technology | Sequencing | Sequencing | Sequencing |
Variant Class | Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Transcript Variants | Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Transcript Variants | Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Somatic Variants |
* 2020年3月現在、Pierian Clinical Knowledgebaseに基づく。
TruSight Oncology 500 Analytical Evaluation Service*により、最新のCAP、AMPおよび欧州基準に準じる際にガイドとなることを目的としたツールです。解析性能特性を評価し、ワークフローに製品を統合しやすくするために推奨しています。
詳細はこちら* 本サービスは、一部の国と地域で利用可能です。
腫瘍横断型バイオマーカー NTRK1 NTRK2 NTRK3 MSI TMB |
|||||||
---|---|---|---|---|---|---|---|
肺がん | 黒色腫 | 結腸がん | 卵巣がん | 乳がん | 胃がん | 膀胱がん | 肉腫 |
AKT1 | BRAF | AKT1 | BRAF | AKT1 | BRAF | MSH5 | ALK |
ALK | CTNNB1 | BRAF | BRCA1 | AR | KIT | PMS2 | APC |
BRAF | GNA11 | HRAS | BRCA2 | BRCA1 | KRAS | TSC1 | BRAF |
DDR2 | GNAQ | KRAS | KRAS | BRCA2 | MET | CDK4 | |
EGFR | KIT | MET | PDGFRA | ERBB2 | MLH1 | CTNNB1 | |
ERBB2 | MAP2K1 | MLH1 | FOXL2 | FGFR1 | PDGFRA | ETV6 | |
FGFR1 | NF1 | MSH2 | TP53 | FGFR2 | TP53 | EWSR1 | |
FGFR3 | NRAS | MSH6 | PIK3CA | FOXO1 | |||
KRAS | PDGFRA | NRAS | PTEN | GLI1 | |||
MAP2K1 | PIK3CA | PIK3CA | KJT | ||||
MET | PTEN | PMS2 | MDM2 | ||||
NRAS | TP53 | PTEN | MYOD1 | ||||
PIK3CA | SMAD4 | NAB2 | |||||
PTEN | TP53 | NF1 | |||||
RET | PAX3 | ||||||
TP53 | PAX7 | ||||||
PDGFRA | |||||||
PDGFRB | |||||||
SDHB | |||||||
SDHC | |||||||
SMARCB1 | |||||||
TFE3 | |||||||
WT1 |
本表に記載された遺伝子およびバイオマーカーは本パネルに含まれる全遺伝子の一部です。全遺伝子リストを確認するには、本ページの製品に関する文献の下にある製品データシートをご覧ください。
* DNAとRNAバリアントを評価するための製品は、TruSight Oncology 500 DNA/RNA Bundleです。
Simplifying the process to identify applicable variants in oncology samples
Brochure | PDF 2 MB
Analysis of TMB and MSI Status with TruSight Oncology 500
Application Note | HTML
Optimizing RNA input to detect gene fusions with TruSight Oncology 500 High-Throughput
Technical Note | PDF < 1 MB
Input Recommendations for TMB, MSI, and Small Variant Analysis with TruSight Oncology 500
Technical Note | HTML
TruSight Oncology 500 Gene List
product_file | EXCEL < 1 MB
Data analysis and reporting for the TruSight Oncology 500 portfolio
Product Information Sheet | PDF 1 MB
Data Sheet | PDF | 7 versions
Data Sheet | PDF | 6 versions
DRAGEN TruSight Oncology 500 Analysis Software v2.1 Documentation
DRAGEN TruSight Oncology 500 Analysis Software v1.1 Documentation
DRAGEN TruSight Oncology 500 Analysis Software v1.1 on ICA Documentation
TruSight Oncology 500 v1.0 Local App Documentation
TruSight Oncology 500 Analysis Software Documentation
TruSight Oncology 500 v2.0 Local App Documentation
TruSight Oncology 500 Support Documentation
TruSight Oncology 500 v2.1 Local App Documentation
* Based on PierianDx Clinical knowledgebase, as of March 2020